ERBB2 and extramammary Paget disease: We retrospectively analyzed the treatment outcomes of patients with metastatic EMPD in relation to the clinical and pathological/molecular features, including HR and HER2 expression, along with systemic treatment outcomes for molecular-targeted therapies.